Biosynthetic glycoprotein populations
AssigneeJanssen Biotech, Inc.
InventorsRajkumar GANESAN, Adam ZWOLAK, Jason HO, Natasa OBERMAJER, Michael DIEM, Sanjaya SINGH, Sathyadevi VENKATARAMANI, Theresa MCDEVITT, Fei SHEN
Life of this patent
Estimating the term…
Abstract
A population of antibodies, wherein less than 80% of the oligosaccharides covalently attached to the population of the antibodies via N297 residues thereof comprise a core fucose residue; and wherein the population of the antibodies comprises an antibody which Fc region comprises K338A and T437R mutations, or K248E and T437R mutations.
Claims24
A population of antibodies,
- (i) wherein less than 80% of the oligosaccharides covalently attached to the population of the antibodies via N297 residues thereof comprise a core fucose residue;
- and
- (ii) wherein the population of the antibodies comprises an antibody which Fc region comprises K338A and T437R mutations, or K248E and T437R mutations (RE mutations),
- wherein amino acid residue numbering is according to the EU numbering system, and
- wherein optionally each antibody in the polulation of the antibodies comprises the RE mutations.
-8. (canceled)
A population of antibodies comprising an antibody, wherein the oligosaccharide covalently attached to the antibody via N297 residues thereof does not comprise a core fucose residue;
- and wherein the antibody comprises an Fc region comprising K338A and T437R mutations, or K248E and T437R mutations (RE mutations), wherein amino acid residue numbering is according to the EU numbering system.
(canceled)
The population of the antibodies of claim1, wherein the population of the antibodies have both enhanced antibody-dependent cellular cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).
-19. (canceled)
(canceled)
A population of antibodies,
- (i) wherein less than 80% of the oligosaccharides covalently attached to the population of the antibodies via N297 residues thereof comprise a core fucose residue;
- and
- (ii) wherein the population of the antibodies comprises an antibody having one or more mutations in the Fc region thereof for increasing CDC activity of the antibody.
(canceled)
-30. (canceled)
(canceled)
Dependencies are inferred from the claim text.